SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

BACKGROUND: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). METHODS: We simplifi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Med (N Y)
Main Authors: Vogels, Chantal B.F., Watkins, Anne E., Harden, Christina A., Brackney, Doug E., Shafer, Jared, Wang, Jianhui, Caraballo, César, Kalinich, Chaney C., Ott, Isabel M., Fauver, Joseph R., Kudo, Eriko, Lu, Peiwen, Venkataraman, Arvind, Tokuyama, Maria, Moore, Adam J., Muenker, M. Catherine, Casanovas-Massana, Arnau, Fournier, John, Bermejo, Santos, Campbell, Melissa, Datta, Rupak, Nelson, Allison, Dela Cruz, Charles S., Ko, Albert I., Iwasaki, Akiko, Krumholz, Harlan M., Matheus, J.D., Hui, Pei, Liu, Chen, Farhadian, Shelli F., Sikka, Robby, Wyllie, Anne L., Grubaugh, Nathan D.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier Inc. 2021
Assuntos:
Clinical and Translational Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7836249/
https://ncbi.nlm.nih.gov/pubmed/33521748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.medj.2020.12.010
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares